Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Etteplan acquires STRONGIT ApS, a Danish consultancy company – a direct share issue to the owners of the acquired company as part of the purchase price

ETTEPLAN OYJ, Stock exchange release, January 8, 2024, 10:20 a.m. EET  Etteplan acquires STRONGIT ApS, a Danish consultancy company – a direct share issue to the owners of the acquired company as part of the purchase price  Etteplan strengthens its market position in Denmark and acquires STRONGIT ApS, a technology services company focusing on product development solutions. The successful acquisition marks a continuation in Etteplan’s strategic growth journey as it complements our expertise and further expands our international operations.  As part of the financing of the

BioStock: Alzinova's CMO wants to bring forward a vaccine against Alzheimer's

Last fall, Dr Kirsten Harting joined Alzinova as the new Chief Medical Officer (CMO). Harting brings profound expertise from working with brain disorders including Alzheimer’s disease as well as knowledge about vaccines and immunotherapy. Roughly a half year into her tenure as CMO, BioStock reached out to Kirsten to learn more about her ambitions to shape Alzinova’s trajectory as the company advances in its Alzheimer’s clinical trials.Read the full interview with Kirsten Harting at biostock.se: https://www.biostock.se/2024/01/alzinovas-cmo-wants-to-bring-forward-a-vaccine-against-

Assemblin in Norway strengthens ventilation installation capacity with an acquisition

Assemblin's Norwegian operations have acquired the ventilation company Skaugen Blikk og Ventilasjon with operations in the Drammen region, an annual turnover of approximately 15 MNOK and 7 employees.Skaugen Blikk og Ventilasjon was established in 1999 and is a strong ventilation company with high competence. The head office is located in Hokksund, where the business also includes a specialised workshop. Among customers are several ventilation contractors and smaller construction contractors in the Drammen region. "We have had a high order intake in 2023 and wish to strengthen our

Diamyd Medical gains market research findings to guide U.S. commercial strategy

Market research including initial interviews with US health care practioners as well as US payers demonstrated a strong willingness to consider prescribing the investigational precision medicine Diamyd[®] for Type 1 Diabetes and pricing in the range of USD 200,000. Diamyd[®] is currently being evaluated in the registrational Phase 3 trial DIAGNODE-3 in patients recently diagnosed with Type 1 Diabetes that carry the HLA DR3-DQ2 haplotype."These results both confirm and exceed our previous insights regarding pricing and the market potential of Diamyd in the US”, says Ulf Hannelius, CEO of

Repurchase of Truecaller B shares in week 1, 2024

During 2 January 2024 and 5 January 2024 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 243,000 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 7 June 2023. The share buyback programme will run between 7 June up until the 2024 AGM which will be held in May 2024, and is carried out in accordance “Emittentregelverket”. On the Annual General Meeting 2023 the Board was authorized to buy back B-shares up until the

Buybacks of shares in ITAB during week 1 2024

During the period between 2 and 5 January 2024, ITAB Shop Concept AB (publ) (”ITAB”) (LEI-code: 2138001H6FCSZBP26351) has repurchased in total 48,964 own ordinary shares (ISIN: SE0015962097) as part of the share buyback program initiated by the Board of Directors in order to optimise the capital structure.The share buybacks form part of the share buyback program in a maximum amount of MSEK 50 that ITAB announced on 28 September 2023. The share buyback program, which runs from 29 September 2023 until 14 May 2024, is being carried out in accordance with the EU Market Abuse Regulation (“MAR”)

Rejlers part of a consortium that signs significant framework agreements with Statnett

The consortium, led by Multiconsult, and the companies Rejlers, EFLA, Metier, Jøsok, Sitepartner and Regio 360, has recently entered into several extensive framework agreements with Statnett to further develop and expand the Norwegian electricity grid. The agreements, which are valid for four years with an option for a further four years, enable Rejlers to deliver technical consulting services in areas that are important for Norway's energy transition.The demand for electrification of Norway, where decarbonisation is central, has increased the need for a significant expansion of the

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseJanuary 8, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On January 5, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |105,487 |4.1066

BioStock: Arcede aims for clinic with TO1

Preparations for clinical trials continue for the Lund-based drug developer Arcede Pharma. Right now, the focus is on finding the right dose and concentration of RCD405 to use in the upcoming phase I studies. January 8 to 19 is the exercise period for the TO1 warrant, which is intended to finance the preparations.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/arcede-aims-for-clinic-with-to1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Calliditas Therapeutics provides business update ahead of JP Morgan conference

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rare diseases today provided a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financial information for the fourth quarter and full year 2023, as follows:· Strong Q4 preliminary product revenue growth with net TARPEYO revenues of $31 – 33m for the quarter, representing significant growth over Q3. · Preliminary Net TARPEYO revenues of $100 – 102m for 2023, representing over 170% year over year growth compared to 2022. ·

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation’s stock exchange release on January 8, 2024, at 9:05 a.m. EETMetso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On January 4, 2024, BlackRock's holding in Metso’s shares fell below the 5 percent threshold. Metso’s total number of shares and voting rights is 828,972,440.BlackRock, Inc.’s holdings according to the notification: % of % of shares and voting rights Total of both shares through

Transaction in Own Shares

    8 January 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |05/01/2024|+------------------------------------------------------------

BlueNord: Preliminary Production for December 2023 and Full Year 2023

Oslo, 8 January 2024: BlueNord ASA ("BlueNord" or the "Company") has today announced its preliminary production figures for December 2023 and for the full year of 2023. The Company had a preliminary production in December of net 24.1 mboepd. The production during the month was stable across all producing hubs, and in particular strong on the Halfdan and Gorm hubs delivering a preliminary operational efficiency above 90%. The preliminary production for the full year of 2023 was 24.9 mboepd which is in the upper range of the yearly production guidance of 24.5 – 25.0 mboepd. This

Preventing the destruction of Eucalyptus forest plantations: naturally occurring pathogenic fungi to control the Eucalyptus snout beetle

Scientists have found naturally occurring pathogenic fungi infecting the Eucalyptus snout beetle in Eucalyptus forest plantations, and characterised them to develop a bio-pesticide for controlling the beetle. Gonipterus platensis, or the Eucalyptus snout beetle, has a heavy impact on Eucalyptus forest plantations worldwide, and it is mostly controlled using the micro wasp Anaphes spp., although control rates rarely become financially viable. This led a team of scientists to look for naturally occurring pathogenic fungi to tackle the Eucalyptus snout beetle problem. Worldwide, the

Clas Ohlson’s sales in December increased compared to the previous year

Sales in December, excluding the acquired Spares Group, increased by 11 per cent to 1,366 MSEK (1,234). Organic sales increased by 14 per cent compared to the previous year.Sales in comparable units and local currency increased by 14 per cent compared to the previous year. Sales, including Spares Group amounted to 1,422 MSEK (1,234). Online sales, excluding Spares Group increased by 22 per cent to 142 MSEK (116). Online sales, including Spares Group amounted to 197 MSEK (116). Compared to the same month last year the store network decreased by 1 store. At the end of the period, the total

Calliditas Therapeutics appoints Maria Törnsén as President North America

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO.Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager

Calliditas to present at JP Morgan Healthcare Conference

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California. Calliditas will present an update on the company at 7:30 am PT on Tuesday 9th January. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com The information was sent for publication, through the agency of the

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

· Strong revenue generation in Q4 2023, including SEK 43m in Idefirix[®] product sales supported by growth in new markets such as U.K., Germany, and Spain · Encouraging first results from first-in-human trial of HNSA-5487, Hansa’s lead candidate from the NiceR program for repeat dosing · Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s SRP-9001 in DMDLund, January 6, 2024. Hansa Biopharma today announced a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financials for the fourth quarter and full year 2023. Søren Tulstrup,

BAKKAFROST: Q4 2023 Trading Update

In Q4 2023 the harvest volumes for Bakkafrost’s operation in the Faroe Islands and Scotland were: Faroe Islands: 16.0 thousand tonnes · Farming North   10.5 thousand tonnes · Farming West     3.9 thousand tonnes · Farming South    1.7 thousand tonnes Scotland: 1.1 thousand tonnes · North   1.0 thousand tonnes       · South   0.0 thousand tonnes The total harvest for 2023 in the Faroe Islands was 52.4 thousand tonnes and in Scotland the total harvest in 2023 was 20.6 thousand tonnes. The total harvest from the Bakkafrost Group in 2023 was 73.0 thousand tonnes.

Tele Radio opens its 26th subsidiary in Denmark

Gothenburg, January 6th, 2024 Further increasing its worldwide network in the field of wireless, industrial remote controls, the Tele Radio Group announces the opening of a new subsidiary in Denmark. Tele Radio Denmark ApS, based in Svenstrup near Aalborg, will be the 26th subsidiary and has opened its doors officially on December 1st, 2023.Helene Kyo Johansen will lead Tele Radio Denmark as its General Manager and Sales Manager. Helene has a successful 13-year trajectory as product manager in Tele Radio’s sister company Åkerströms as well as 20 years of sales experience throughout her

New COVID vaccine induces good antibody response to mutated viral variants

Researchers at Karolinska Institutet and Danderyd Hospital in Sweden have followed recipients of the new updated COVID-19 vaccine and analysed the antibody response to different SARS-CoV-2 variants. The results published in The Lancet Infectious Diseases show a surprisingly strong response to the now dominant and highly mutated Omicron variants.The ongoing COMMUNITY study , which was launched in the spring of 2020 with the regular testing of 2,149 members of the Danderyd Hospital staff, has recently published the results of this autumn’s leg of the study.

Nordea Bank Abp: Repurchase of own shares on 05.01.2024

Nordea Bank AbpStock exchange release – Changes in company’s own shares05.01.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 05.01.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |59,382 |11.62 |690,292.00

Prostatype Genomics announces preliminary outcome of the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION FURTHER REQUIRES PROSPECTUS, REGISTRATION, OR OTHER ACTIONS OTHER THAN THOSE UNDER SWEDISH LAW, ARE PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT TAKE PLACE WITHOUT APPLICATION OF EXCEPTIONS FROM SUCH ACTION. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Transaction in Own Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 05 January 2024 REDDE NORTHGATE PLC (“Redde Northgate” or the “Group” or the “Company”)   Transaction in Own Shares   Redde Northgate plc (LSE:REDD) announces that on 05 January 2024 it purchased the following number of its own shares to be held in treasury:   Class of shares :  Ordinary shares of 50p (“shares”)

There are no items matching the current filter
There are no more items matching the current filter
Back to top